Groundbreaking approaches in oncology are emerging, including engineered bacteria delivering oncolytic viruses directly into tumors, bypassing immune defenses for targeted destruction, and Anocca’s $46M funding to advance early-phase TCR cell therapy trials for KRAS-mutant pancreatic cancer. Additional studies demonstrate that c-Abl inhibition significantly arrests glioma cell propagation, a finding published in BMC Cancer that could inform targeted glioma treatments. These multi-modal strategies exemplify the frontier in cancer therapeutics aiming to overcome treatment resistance and improve patient outcomes.